Osama Saleh, MD
Psychiatry · Prince Frederick, MDNPI 1093785347
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 1,006 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,006 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$2K
- Supernus Pharmaceuticals, Inc.$2K
- Lundbeck LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$1K
- Sunovion Pharmaceuticals Inc.$864
- plus $6K from 29 others
What the payments were for
- Speaking & faculty fees$5003%
- Food & beverage$13,93796%
- Education$700%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,507 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 42 | $353,534 |
| RexultiBrexpiprazole | 48 | $93,846 |
| CaplytaLumateperone Tosylate | 36 | $59,511 |
| FanaptIloperidone | 26 | $55,419 |
| VraylarCariprazine Hcl | 25 | $37,803 |
| UzedyRisperidone | 15 | $37,253 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 134 | $32,851 |
| Lurasidone Hcl | 21 | $27,331 |
| TrintellixVortioxetine Hydrobromide | 43 | $27,055 |
| OzempicSemaglutide | 23 | $23,964 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 30 | $23,060 |
| Aripiprazole | 268 | $12,573 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 318 | $12,425 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 97 | $10,381 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $8,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,098 | $353,53442 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $562 | $93,84648 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,395 | $59,51136 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,739 | $55,41926 claims |
| AbbVieVraylar | $728 | $37,80325 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $223 | $37,25315 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $218 | $32,68257 claims |
| Orexo US, Inc.Zubsolv | $99 | $23,06030 claims |
| Indivior Inc.Suboxone | $633 | $8,29019 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $13 | $5,57912 claims |
| Almatica Pharma LLCSertraline Hcl | $27 | $2,480355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Prince Frederick
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
- Akira SawaBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.